- Home
- SVRA
SVRA
Savara Inc.
as 12-20-2024 4:00pm EST
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 590.4M | IPO Year: | N/A |
| Target Price: | $9.86 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.81 - $5.70 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Savara Inc. (SVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pauls Matthew | SVRA | CHIEF EXECUTIVE OFFICER | Dec 12 '24 | Sell | $3.31 | 54,702 | $180,828.40 | 1,536,379 | |
| Lowrance David L | SVRA | Chief Financial Officer | Dec 12 '24 | Sell | $3.33 | 25,000 | $83,277.50 | 381,005 | |
| Hawkins Richard J | SVRA | Director | Dec 12 '24 | Sell | $3.32 | 8,000 | $26,568.80 | 67,241 | |
| McCracken Joseph S | SVRA | Director | Nov 19 '24 | Buy | $2.95 | 20,000 | $59,072.00 | 210,837 | |
| RAMSAY DAVID A | SVRA | Director | Nov 18 '24 | Buy | $2.88 | 100,000 | $287,600.00 | 2,323,642 |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target
MT Newswires
4 days ago
Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate
Business Wire
4 days ago
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire
5 days ago
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
a month ago
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)
Business Wire
a month ago
Savara Announces New Employment Inducement Grant
Business Wire
a month ago
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 11/21/2024
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.